Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Intellia Therapeutics
Biotech
Intellia races in vivo CRISPR therapy to FDA after phase 3 win
William Blair analysts called lonvo-z a “compelling one-time option" after seeing the phase 3 data.
Nick Paul Taylor
Apr 27, 2026 9:24am
FDA fully releases clinical hold on Intellia CRISPR trials
Mar 2, 2026 10:55am
FDA frees Intellia of 1 clinical hold for CRISPR therapy
Jan 27, 2026 10:54am
Patient dies after receiving Intellia's CRISPR therapy
Nov 7, 2025 5:25am
FDA puts Intellia CRISPR trials on hold over raised liver enzyme
Oct 30, 2025 6:37am
Intellia pauses phase 3 CRISPR trials after patient hospitalized
Oct 27, 2025 9:45am
